Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.16 USD
Change Today +0.0004 / 0.26%
Volume 224.0K
HEB On Other Exchanges
As of 8:04 PM 10/8/15 All times are local (Market data is delayed by at least 15 minutes).

hemispherx biopharma inc (HEB) Snapshot

Previous Close
Day High
Day Low
52 Week High
10/13/14 - $0.40
52 Week Low
08/24/15 - $0.14
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

hemispherx biopharma inc (HEB) Related Bloomberg News

View More Bloomberg News

hemispherx biopharma inc (HEB) Related Businessweek News

No Related Businessweek News Found

hemispherx biopharma inc (HEB) Details

Hemispherx Biopharma, Inc., a specialty pharmaceutical company, engages in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States. The company’s primary products comprise Ampligen, an experimental drug, which is under clinical development for the treatment of chronic fatigue syndrome, Hepatitis B, HIV, renal cell carcinoma, and malignant melanoma; and Alferon N Injection, an injectable formulation of natural alpha interferon for the treatment of certain categories of genital warts. It is also developing Alferon LDO, a low-dose oral liquid formulation of natural alpha interferon for the treatment of pandemic influenza, seasonal influenza, and other emerging viruses. The company has a strategic alliance with Bioclones (Pty) Ltd. to develop various projects. Hemispherx Biopharma, Inc. was founded in 1990 and is headquartered in Philadelphia, Pennsylvania.

37 Employees
Last Reported Date: 03/19/15
Founded in 1990

hemispherx biopharma inc (HEB) Top Compensated Officers

Chairman, Chief Executive Officer, Chief Scie...
Total Annual Compensation: $1.9M
Executive Vice Chairman, President, Chief Fin...
Total Annual Compensation: $1.3M
Chief Medical Officer and Medical Director
Total Annual Compensation: $336.8K
Compensation as of Fiscal Year 2014.

hemispherx biopharma inc (HEB) Key Developments

Hemispherx Biopharma, Inc. Announces Update on the Case Brought by Cato Capital

Hemispherx Biopharma, Inc. announced that on August 28, 2015, the Third Circuit Court of Appeals upheld the company's successful defense of a case brought by Cato Capital, thus affirming the trial court judgment Hemispherx obtained in September 2014, when the Company fully prevailed in a federal lawsuit brought against the company following trial. The appellate panel affirmed the United States District Court for the District of Delaware, which had dismissed all claims against Hemispherx and subsequently ordered Cato to pay Hemispherx attorney's fees and costs in the amount of $770,852.76.

Hemispherx Biopharma Extends its Strategic Alliance with Armada Health Care for Alferon N Injection(R)

Hemispherx Biopharma, Inc. announced that as the company works toward the re-launch of Alferon N, it has extended its agreement with Armada Health Care, LLC for two years (through August 14, 2017) for the sales/marketing of Alferon N Injection, its Food and Drug Administration approved natural interferon, in the U.S. Under this Agreement, the Company will manufacture and supply Alferon N Injection to physicians and patients through Armada's national network of specialty pharmacies. Armada has agreed to provide ongoing sales and marketing to support the product's re-launch. Specialty Distributor, BioRidge Pharma, LLC ("BRP"), has received a two year contract extension and will warehouse, ship, and distribute Alferon N Injection on an exclusive basis for U.S. sales.

Hemispherx Biopharma, Inc. Reports Earnings Results for the Second Quarter and First Half Ended June 30, 2015

Hemispherx Biopharma, Inc. reported earnings results for the second quarter and first half ended June 30, 2015. For the first half, the company's net loss narrowed to $8.3 million, or $0.04 per share, from $8.8 million, or $0.05 per share for the six-month period ended June 30, 2014. Total revenues for the six months ended June 30, 2015 were $83,000, compared to $112,000 for the same period ended June 30, 2014. The company reported that net loss for the second quarter ended June 30, 2015 was $4.84 million, or $0.02 loss per share, compared to a net loss of $4.96 million, or $0.03 loss per share, for the same quarter ended June 30, 2014. Total revenues for the second quarter ended June 30, 2015 were $47,000, compared to $36,000 for the same quarter ended June 30, 2014.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HEB:US $0.16 USD +0.0004

HEB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Allergan plc $276.16 USD +7.17
AstraZeneca PLC 4,161 GBp +48.50
Baxter International Inc $33.25 USD +0.34
Medigene AG €6.44 EUR -0.158
Sarepta Therapeutics Inc $37.81 USD -0.16
View Industry Companies

Industry Analysis


Industry Average

Valuation HEB Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 228.4x
Price/Book 1.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 145.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HEMISPHERX BIOPHARMA INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at